AMRX
AmnealBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that Q1 momentum is real, FY2026 guidance stays intact, and Kashiv adds scale and biosimilars optionality without disrupting execution. If those pieces hold, the stock can justify a rerating toward the current median target.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -0.7.
What can break
Kashiv close and integration risk: regulatory approvals, milestone realization, and post-close execution could delay or dilute the expected biosimilars uplift.
Momentum
42
Value
66
Sentiment
78
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $16.80 · Bull $20.00 · Bear $9.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-27 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $16.80
Why
Momentum42 · Δ7d +4.6
Value66 · Δ7d +0.0
Sentiment78 · Δ7d -0.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
42
34% active weight
Current posture
7d trendImproving
Δ7d
+4.6
Δ21d
-4.8
Value
66
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.3
Sentiment
78
33% active weight
Current posture
7d trendFlat
Δ7d
-0.7
Δ21d
+22.4
Why this grade
Composite grade B. Momentum 42.1 / Value 65.7 / Sentiment 78.2
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$4.12B
Beta
1.36
Shares Out
314.36M
P/E (TTM)
769.4
P/S (TTM)
1.36
P/FCF (TTM)
16.89
Rev YoY
+11.7%
EPS YoY
+1558.0%
Gross Margin
+36.8%
Op Margin
+12.2%
Net Debt
$2.44B
Current Ratio
2.13
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology